Otitis Media - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 76 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Otitis Media - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Otitis Media - Pipeline Review, H2 2014', provides an overview of the Otitis Media's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Otitis Media
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Otitis Media and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Otitis Media products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Otitis Media pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Otitis Media
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Otitis Media Overview 7
Therapeutics Development 8
Pipeline Products for Otitis Media - Overview 8
Pipeline Products for Otitis Media - Comparative Analysis 9
Otitis Media - Therapeutics under Development by Companies 10
Otitis Media - Therapeutics under Investigation by Universities/Institutes 12
Otitis Media - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Otitis Media - Products under Development by Companies 16
Otitis Media - Products under Investigation by Universities/Institutes 17
Otitis Media - Companies Involved in Therapeutics Development 18
GlaxoSmithKline plc 18
Cubist Pharmaceuticals, Inc. 19
Yuhan Corporation 20
Arbor Pharmaceuticals, LLC. 21
Otonomy, Inc. 22
Cellceutix Corporation 23
Serum Institute of India Limited 24
ContraFect Corporation 25
BCO Pharma Ltd 26
Otitis Media - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ciprofloxacin SR - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AR-01 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GSK-2189242A - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
betahistine hydrochloride - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SIILPCV-10 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
P-13 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
brilacidin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
solithromycin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BCO-002 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
YH-1177 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CF-309 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Otitis Media - Recent Pipeline Updates 52
Otitis Media - Dormant Projects 67
Otitis Media - Product Development Milestones 68
Featured News & Press Releases 68
Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery 68
May 08, 2014: Otonomy Completes Enrollment of AuriPro Pivotal Studies in Pediatric Patients Undergoing Ear Tube Placement Surgery 68
Feb 24, 2014: Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections 69
Dec 11, 2013: Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery 70
Aug 20, 2013: Otonomy Announces Positive Phase 1b Results for OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery 70
Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections 71
Jun 12, 2012: Venus Remedies's Antibiotic Drug CSE1034 Obtains US Patent 72
Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media 73
Jan 16, 2012: Pergamum Initiates Phase II Trial With DPK-060 In Outer Ear Infections 73
Jun 08, 2011: Otonomy Announces Positive Preclinical Results For OTO-201 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables
Number of Products under Development for Otitis Media, H2 2014 8
Number of Products under Development for Otitis Media - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Otitis Media - Pipeline by GlaxoSmithKline plc, H2 2014 18
Otitis Media - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 19
Otitis Media - Pipeline by Yuhan Corporation, H2 2014 20
Otitis Media - Pipeline by Arbor Pharmaceuticals, LLC., H2 2014 21
Otitis Media - Pipeline by Otonomy, Inc., H2 2014 22
Otitis Media - Pipeline by Cellceutix Corporation, H2 2014 23
Otitis Media - Pipeline by Serum Institute of India Limited, H2 2014 24
Otitis Media - Pipeline by ContraFect Corporation, H2 2014 25
Otitis Media - Pipeline by BCO Pharma Ltd, H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Otitis Media Therapeutics - Recent Pipeline Updates, H2 2014 52
Otitis Media - Dormant Projects, H2 2014 67